Gudjonsson, J.E., Ding, J., Johnston, A., Tejasvi, T., Guzman, A.M., Nair, R.P., et al. (2010) Assessment of the Psoriatic Transcriptome in a Large Sample: Additional Regulated Genes and Comparisons with in Vitro Models. Journal of Investigational Dermatology, 130, 1829-1840.
http://dx.doi.org/10.1038/jid.2010.36

has been cited by the following article:

• TITLE: Efficacy and Safety of Tinefcon® Tablets in Subjects with Plaque Psoriasis: An Open Label, Non-Comparative, Multicenter, Phase IV Trial

  AUTHORS: Somesh Sharma, Kailash Bhatia, Meetesh Agarwal, Sandesh Gupta, Leelavathi Budamakuntla, Sudhakar Grandhi, Vinod Titarmare, Sushil Pande, Ranjan Rawal, Aruna Samarth, Rizwan Haq, Vikrant Saoji, D. V. S. Pratap, L. M. Kansal, D. G. Saple, Shatrughan Sahay, Parag Kalyani, Puneet Goyal, Sharmila Patil, A. J. Kanwar, Bhavesh Swarnakar, Sujay Kulkarni, Abhijeet Morde, Hitesh Khandagale, Yogesh Dound, Nitin Jadhav, Sanjeev Hegde, Murlidhara Padigaru, Ashish C. Suthar

  KEYWORDS: Psoriasis, Tinefcon® Tablet, Sphaeranthus indicus

  JOURNAL NAME: Journal of Cosmetics, Dermatological Sciences and Applications, Vol.6 No.2, April 25, 2016

  ABSTRACT: Importance: This post-marketing surveillance study was conducted to evaluate real-world information about the efficacy and safety of oral Tinefcon? tablets (Sphaeranthus indicus based) in plaque psoriasis patients. Materials and Methods: Patients aged at least 18 years and older with clinical diagnosis of plaque psoriasis, were enrolled in this open label, non-comparative, multicenter trial. All eligible subjects received four 700 mg Tinefcon? tablets/day for 12 weeks. The primary outcome measure was percent change in Psoriasis Area Severity Index (PASI) score from baseline to week 12. The secondary outcome measures were Physician Global Assessment (PGA), Nail Psoriasis Severity Index (NAPSI), Psoriatic Arthritis Evaluation and Gene Expression Profiling and Immunohistochemistry. Results: After completion of Tinefcon? treatment at 12 weeks, more than half of subjects (52%) achieved PASI 50 response; PASI 75 response was attained in 68 (23%) subjects and PASI 90 response in 22 (7%) subjects. Five subjects with severe psoriasis achieved PASI 90 without receiving any concomitant medication. Reduction in severity as assessed by PGA was observed in more than half of patients with moderate disease. Histopathological evaluation revealed that epidermal thickness was considerably reduced in 66% of subjects. The expression of inflammatory marker S100A9 protein was(meaningfully reduced in 60% patients with non-significant reduction of Keratin 10 protein expression. Gene expression analysis showed increase down regulation of SERPINB4; PI3 and KRT16 genes after a 12-week treatment period in subjects with higher PASI scores. Conclusion: Oral Tinefcon? tablets showed good efficacy and had a favorable safety profile in plaque psoriasis patients.